Revelation Biosciences Q1 net loss $3.0M; cash $14.1M; FDA agrees to adaptive Phase 2/3 study

REVELATION BIOSCIENCES, INC.

2026-Q1 EPS reported -$2.71

Net loss $3.0M ($2.71/share) vs $2.1M ($25.34/share) in Q1 2025; operating cash burn $3.2M.
Cash and equivalents $14.1M at March 31, 2026, up from $10.7M at Dec 31, 2025; cash runway through Q1 2027.
FDA agreed to a single adaptive Phase 2/3 study design for Gemini in acute kidney injury patients.
Received $6.7M net proceeds from January 2026 warrant inducement.
Presented positive additional data analysis from PRIME Study at AKI & CRRT 2026 conference.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

REVELATION BIOSCIENCES, INC. reported three months ended March 31, 2026 results: net income $3.0 million, or $2.71 basic and diluted net loss per share.

Period: three months ended March 31, 2026
Net income: $3.0 million, or $2.71 basic and diluted net loss per share
Result: reported results

Exact text from the filing

31, 2026 was $3.2 million compared to net cash used for operating activities of $2.8 million for the same period in 2025. Net loss for the three months ended March 31, 2026 was $3.0 million, or $2.71 basic and diluted net loss per share compared to net loss of $2.1 million, or $25.34 basic and diluted net loss per share for the three months ended March 31, 2025.

View on SEC.gov

Browse all earnings releases →

REVELATION BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-212064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.